4 Sources
[1]
Using AI to measure prostate cancer lesions could aid diagnosis and treatment
Prostate cancer is the second most common cancer in men, and almost 300,000 individuals are diagnosed with it each year in the U.S. To develop a consistent method of estimating prostate cancer size, which can help clinicians more accurately make informed treatment decisions, Mass General Brigham
[2]
Using AI to measure prostate cancer lesions could aid diagnosis and treatment
Prostate cancer is the second most common cancer in men, and almost 300,000 individuals are diagnosed with it each year in the U.S. To develop a consistent method of estimating prostate cancer size, which can help clinicians more accurately make informed treatment decisions, Mass General Brigham
[3]
AI model could help clinicians to understand prostate tumor's aggressiveness
Mass General BrighamOct 29 2024 Prostate cancer is the second most common cancer in men, and almost 300,000 individuals are diagnosed with it each year in the U.S. To develop a consistent method of estimating prostate cancer size, which can help clinicians more accurately make informed treatment
[4]
How AI Might Help Men Fighting Prostate Cancer
TUESDAY, Oct. 29, 2024 (HealthDay News) -- Artificial intelligence might be able to help doctors detect the prostate cancers most likely to be life-threatening to men, a new study suggests. An AI program successfully identified and outlined 85% of the most aggressive prostate tumors seen on MRI
Share
Copy Link
Researchers at Mass General Brigham have developed an AI model that can accurately measure prostate cancer lesions from MRI scans, potentially improving diagnosis, treatment planning, and outcome prediction for patients.

Researchers at Mass General Brigham have developed an artificial intelligence (AI) model that could revolutionize the diagnosis and treatment of prostate cancer, the second most common cancer in men. The model, trained on MRI scans from over 700 prostate cancer patients, has shown remarkable accuracy in identifying and measuring aggressive prostate lesions
1
.The AI model successfully identified and demarcated the edges of 85% of the most radiologically aggressive prostate lesions. Importantly, tumors with larger volumes, as estimated by the AI, were associated with a higher risk of treatment failure and metastasis, independent of other traditional risk factors
2
.Dr. David D. Yang, the study's first author, emphasized the potential of this technology: "AI-determined tumor volume has the potential to advance precision medicine for patients with prostate cancer by improving our ability to understand the aggressiveness of a patient's cancer and therefore recommend the most optimal treatment"
3
.The AI model offers several advantages over current methods:
Consistency: Unlike human estimates, which can be subjective and vary between clinicians, the AI provides consistent measurements
1
.Speed: The AI-informed testing is significantly faster than current methods, which typically take two weeks or longer to yield results
4
.Prognostic value: For patients receiving radiation therapy, the tumor volume estimated by AI performed better than traditional risk stratification in predicting metastasis
2
.Related Stories
The AI model could have far-reaching implications for prostate cancer treatment:
Personalized treatment plans: By providing a more accurate assessment of tumor aggressiveness, the AI could help clinicians tailor treatments to individual patients
3
.Guided radiation therapy: The model could assist radiation oncologists by pinpointing the tumor's focal region for more targeted treatment
4
.Earlier treatment initiation: The faster results provided by AI-informed testing could allow patients to begin treatment sooner
1
.While the results are promising, the researchers emphasize the need for further validation. Dr. Yang stated, "We want to validate our findings, using other institutions and patient cohorts with different disease characteristics, to make sure that this approach is generalizable to all patients"
3
.The team plans to test their model with a larger, multi-institutional dataset to ensure its applicability across diverse patient populations. This research aligns with Mass General Brigham's vision of providing comprehensive, integrated, and research-informed cancer care, with a focus on health equity
2
.Summarized by
Navi
[4]
1
Technology

2
Technology

3
Policy and Regulation
